Andrew D. Dickinson Sells 142,180 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $2.00 during trading on Friday, hitting $96.04. 7,182,199 shares of the company were exchanged, compared to its average volume of 6,916,494. The firm's fifty day moving average price is $92.97 and its 200 day moving average price is $86.49. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a market cap of $119.69 billion, a price-to-earnings ratio of 1,067.11, a PEG ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the prior year, the business posted $2.29 earnings per share. The firm's revenue for the quarter was up 7.0% compared to the same quarter last year. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Barclays boosted their target price on Gilead Sciences from $84.00 to $95.00 and gave the company an "equal weight" rating in a report on Thursday, November 7th. UBS Group boosted their price objective on Gilead Sciences from $70.00 to $96.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. Maxim Group lowered shares of Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Piper Sandler upped their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Finally, BMO Capital Markets raised their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $98.39.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors have recently modified their holdings of the company. nVerses Capital LLC purchased a new stake in Gilead Sciences during the third quarter worth $25,000. HHM Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 154 shares during the last quarter. Valued Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 161 shares in the last quarter. YANKCOM Partnership acquired a new stake in Gilead Sciences in the 4th quarter valued at about $28,000. Finally, Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.